SCHEMBL336035

SCHEMBL336035

C[C@@]12CCC[C@H]1[C@@H]1CC=C3C[C@@H](O)CC[C@]3(C)[C@H]1CC2

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SHBG P04278 4/20 0.64
G6PD P11413 3/20 0.64
SERPINA6 P08185 2/20 0.64
ESR1 P03372 1/20 0.64
AR P10275 1/20 0.64
ESR2 Q92731 1/20 0.64
MEN1 O00255 1/20 0.64
LMNA P02545 1/20 0.64
GUSB P08236 1/20 0.64
CYP3A4 P08684 1/20 0.64
PMP22 Q01453 1/20 0.64
KMT2A Q03164 1/20 0.64
GPBAR1 Q8TDU6 1/20 0.64
TSHR P16473 1/20 0.64
CYP17A1 P05093 9/20 0.64
TBXAS1 P24557 1/20 0.64
SRD5A2 P31213 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18925198 1.00 SHBG (0.64) SHBGG6PDSERPINA6ESR1AR
SCHEMBL9939193 1.00 SHBG (0.64) SHBGG6PDSERPINA6ESR1AR
SCHEMBL14149814 1.00 SHBG (0.64) SHBGG6PDSERPINA6ESR1AR
SCHEMBL3366382 1.00 SHBG (0.64) SHBGG6PDSERPINA6ESR1AR
SCHEMBL12310691 1.00 SHBG (0.64) SHBGG6PDSERPINA6ESR1AR
SCHEMBL23155091 1.00 SHBG (0.64) SHBGG6PDSERPINA6ESR1AR
SCHEMBL13076860 1.00 SHBG (0.64) SHBGG6PDSERPINA6ESR1AR
SCHEMBL13461623 1.00 SHBG (0.64) SHBGG6PDSERPINA6ESR1AR
SCHEMBL11970666 1.00 SHBG (0.64) SHBGG6PDSERPINA6ESR1AR
SCHEMBL336036 1.00 SHBG (0.64) SHBGG6PDSERPINA6ESR1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119486721-A Lipid nanoparticles comprising imidazolium-based cationic lipids 宝利普拉斯生物转染公司 2025-02-18 CN claimed
CN-113473974-A Pharmaceutical composition 深圳市药欣生物科技有限公司 2021-10-01 CN claimed
US-20030113284-A1 Use of DHEA derivatives on keratinous substances L'OREAL (FR) 2003-06-19 US claimed
EP-1306081-A1 Cosmetic use of DHEA-derivatives L'OREAL (FR) 2003-05-02 EP claimed
US-6093389-A CONTAINING A STEROID DERIVATIVE AMERICAN CYANAMID COMPANY (US) 2000-07-25 US claimed
EP-0749977-B1 17-hydroxyiminoalkyl and 17-hydroxyiminomethylalkenyl cyclopentaneperhydrophenanthrene derivatives active on the cardiovascular system, a process for their preparation and pharmaceutical compositions containing same SIGMA TAU IND FARMACEUTI (IT) 1999-08-18 EP claimed
US-5792759-A STEROIDS, USEFUL FOR TREATEMENT OF HEART FAILURE AND HYPERTENSION SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 1998-08-11 US claimed
EP-0846417-A1 Methods and compositions for attracting and controlling termites American Cyanamid Company (US) 1998-06-10 EP claimed
EP-0749977-A2 Novel 17-hydroxyiminoalkyl and 17-hydroxyiminomethylalkenyl cyclopentaneperhydrophenanthrene derivatives active on the cardiovascular system, a process for their preparation and pharmaceutical compositions containing same Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 1996-12-27 EP claimed
EP-0087359-B1 NITROMETHYLATING REAGENT, ITS UTILIZATION IN THE PREPARATION OF NITROMETHYLATED COMPOUNDS AND SOME OF THEIR DERIVATIVES AND THE COMPOUNDS OBTAINED ROUSSEL-UCLAF (FR) 1989-05-31 EP claimed
CN-119486721-A Lipid nanoparticles comprising imidazolium-based cationic lipids 宝利普拉斯生物转染公司 2025-02-18 CN disclosed
CN-119421871-A Ionizable lipids 伊泽阿恩埃免疫疗法股份有限公司 2025-02-11 CN disclosed
CN-119384272-A Freeze-dried RNA composition 伊泽阿恩埃免疫疗法股份有限公司 2025-01-28 CN disclosed
CN-119095588-A Continuous rotary freeze drying of nucleic acid-containing compositions 伊泽阿恩埃免疫疗法股份有限公司 2024-12-06 CN disclosed
CN-118647368-A Method for mass production of large-size LNP 伊泽阿恩埃免疫疗法股份有限公司 2024-09-13 CN disclosed
US-5604213-A STEROID DEPENDENT CANCERS SUCH AS PROSTATE AND BREAST CANCER BRITISH TECHNOLOGY GROUP LIMITED (GB) 1997-02-18 US disclosed
EP-0749977-A2 Novel 17-hydroxyiminoalkyl and 17-hydroxyiminomethylalkenyl cyclopentaneperhydrophenanthrene derivatives active on the cardiovascular system, a process for their preparation and pharmaceutical compositions containing same Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 1996-12-27 EP disclosed
EP-0633893-A1 17-SUBSTITUTED STEROIDS USEFUL IN CANCER TREATMENT BRITISH TECHNOLOGY GROUP LTD (GB) 1995-01-18 EP disclosed
WO-1993020097-A1 17-SUBSTITUTED STEROIDS USEFUL IN CANCER TREATMENT BRITISH TECHNOLOGY GROUP LTD. (GB) 1993-10-14 WO disclosed
EP-0135337-B1 PREVENTIVE AND CURATIVE PREPARATION FOR THROMBOSIS Bellex Corporation (JP) 1989-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030113284-A1 Use of DHEA derivatives on keratinous substances SHBG, CYP21A2, NR5A1 SHBG 1/4885G6PD 343/4885SERPINA6 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.